Gregory Eschenauer is a Clinical Associate Professor in the Department of Clinical Pharmacy at the University of Michigan College of Pharmacy and clinical pharmacy specialist in infectious diseases at Michigan Medicine. Dr. Eschenauer received his Doctor of Pharmacy from Butler University and completed his pharmacy practice and infectious diseases specialty residencies at the University of Michigan. Since completing his residency, Dr. Eschenauer served as an infectious diseases clinical pharmacist at New York Presbyterian Hospital and the University of Pittsburgh Medical Center prior to joining the University of Michigan. He is a Board Certified Pharmacotherapy Specialist with Added Qualifications in Infectious Diseases.

Research Interests

  • Antifungal pharmacotherapy

  • Antimicrobial stewardship

Selected Publications

  • Welch HK, Nagel JL, Patel TS, Tandhi TN, Chen B, De Leon J, Chenoweth CE, Washer LL, Rao K, Eschenauer GA. Effect of an Antimicrobial Stewardship Intervention on Outcomes for Patients with Clostridium difficile Infection. Am J Infect Control 2016;44:1539-1543.

  • Carver PL, Eschenauer GA, Stuckey L, Patel T. Antifungal Prophylaxis in Lung Transplant Recipients. Transplantation 2016;100:1815-1826.

  • Eschenauer GA, Kwak EJ, Potoski BA, Clarke LG, Shields RK, Abdel-Massih R, Silveira FP, Vergidis P, Clancy CJ, Nguyen MH. Targeted versus Universal Antifungal Prophylaxis among Liver Transplant Recipients. Am J Transplant 2015;15:180-9.

  • Eschenauer GA, Nguyen MH, Clancy CJ. Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia. Ann Pharmacotherapy 2015;49:1068-1074.

  • Eschenauer GA, Nguyen MH, Shoham S, Vazquez JA, Morris AJ, Pasculle WA, Kubin CJ, Klinker KP, Carver PL, Hanson KE, Chen S, Lam SW, Potoski BA, Clarke LG, Shields RK, Clancy CJ. Real-world experience with echinocandin MICs against Candida species: A multi-center study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob Agents Chemother 2014;58:1897-906

  • Eschenauer GA, Carver PL, Lin SW, Klinker KP, Chen YC, Potoski BA, Shields RK, Clancy CJ, Nguyen MH, Lam SW. Fluconazole versus echinocandin for Candida glabrata fungemia: A retrospective cohort study. J Antimicrob Chemother 2013;68:922-926.

  • Eschenauer GA, Carver PL. The evolving role of antifungal susceptibility testing. Pharmacotherapy 2013;33:465-475.

  • Eschenauer GA, Lam SW, Carver PL. Antifungal prophylaxis in liver transplant recipients. Liver Transpl 2009;15:842- 858.

  • Lam SW, Eschenauer GA, Carver PL. Evolving role of early antifungals in the intensive care unit. Crit Care Med 2009;37:1580- 1593.

  • Collins CD, Eschenauer GA, Salo S, Newton DW. To test or not to test: A cost-minimization analysis of susceptibility testing in patients with documented Candida glabrata fungemias. J Clin Microbiol 2007;45:1884-1888.